PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 74665

Title: Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 00503561
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Professor
Reviewer’s Country/Territory: Japan
Author’s Country/Territory: China
Manuscript submission date: 2022-02-11
Reviewer chosen by: AI Technique
Reviewer accepted review: 2022-02-25 01:31
Reviewer performed review: 2022-02-25 02:08

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>Grade A: Priority publishing</th>
<th>Grade B: Minor language polishing</th>
<th>Grade C: A great deal of language polishing</th>
<th>Grade D: Rejection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>Accept (High priority)</th>
<th>Accept (General priority)</th>
<th>Minor revision</th>
<th>Major revision</th>
<th>Rejection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Re-review</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
This is an important case report and the point would be that early detection of T760M in CSF by ctDNA NGS. The title could contain this portion.
Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 74665

Title: Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05478444

Position: Peer Reviewer

Academic degree: BSc, MSc, PhD

Professional title: Associate Professor

Reviewer’s Country/Territory: Saudi Arabia

Author’s Country/Territory: China

Manuscript submission date: 2022-02-11

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-05-05 15:25

Reviewer performed review: 2022-05-09 05:59

Review time: 3 Days and 14 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ Y] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ Y] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ Y] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Re-review                   | [ ] Yes | [ Y] No |
SPECIFIC COMMENTS TO AUTHORS

The following case report, entitled: Successful Treatment with Osimertinib in a Patient with Thr790Met-positive Non-Small-Cell Lung Cancer and Leptomeningeal Carcinomatosis Resistant to Gefitinib: A Case Report, presents important and interesting case study. Yet the following points should be addressed before further steps:

Abstract: -Line 33: add LM after (Leptomeningeal). -Line 38: Mention name of the hospital -Line 40: amend: EGFR mutation was detected by the genomic examination -Line 48-49: resulting in a good response, add: (within …months). -Line 51: as the study proved the effect of Osimertinib in one patient, so amend: (patient) not (patients). -Line 51: amend (great clinical benefit) to more specific word, example showing the % of remission. Informed consent statement: Number or date of the Informed consent statement should be mentioned. Keywords: -Line 59-60: I am suggesting the following sequence: non-small cell lung cancer, EGFR mutation, circulating tumor DNA detection, leptomeningeal carcinomatosis, Osimertinib. Abbreviations: -It is important to be consistent when using abbreviations. Every time, first mention the full word then keep mentioning the abbreviation. -Add: Leptomeningeal: LM -Line 93: (targeted oncogenes) should be amended to (target oncogenes). -Line 100: amend to: (meningeal carcinomatosis, which is resistant to gefitinib). -Line 144: specify for how long Osimertinib was used? -Line 167: amend: and could thus be more helpful for. -Line 169: re-write this sentence: Moreover, this report is characteristic of lung cancer. -Line 184: change benefits to (results).
# PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases  
**Manuscript NO:** 74665  
**Title:** Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report  
**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 03072151  
**Position:** Editorial Board  
**Academic degree:** MD, MSc  
**Professional title:** Associate Professor, Attending Doctor, Surgeon  
**Reviewer’s Country/Territory:** Taiwan  
**Author’s Country/Territory:** China  
**Manuscript submission date:** 2022-02-11  
**Reviewer chosen by:** Dong-Mei Wang  
**Reviewer accepted review:** 2022-05-11 23:44  
**Reviewer performed review:** 2022-05-19 02:08  
**Review time:** 7 Days and 2 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SPECIFIC COMMENTS TO AUTHORS

The current case report summarized the Successful Treatment with Osimertinib in a Patient with Thr790Met-positive Non-Small-Cell Lung Cancer and Leptomeningeal Carcinomatosis. I regret to give further positive comments due to the below reasons.

- The signed consent provided is statement to agree for surgery, not for publication of the patient’s material. Moreover, Institutional Review Board statement is missing.
- The core information adds little value to the literature.
- The dosage of Osimertinib applied to the patient was not well explained.
- The follow-up period was too short.
- The effectiveness and safety of Osimertinib is not elucidated and compared with other potential medications.

---

| Peer-reviewer statements | Peer-Review: [Y] Anonymous  [ ] Onymous | Conflicts-of-Interest: [ ] Yes  [Y] No |
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 74665

Title: Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05478444

Position: Peer Reviewer

Academic degree: BSc, MSc, PhD

Professional title: Associate Professor

Reviewer’s Country/Territory: Saudi Arabia

Author’s Country/Territory: China

Manuscript submission date: 2022-02-11

Reviewer chosen by: Li-Li Wang

Reviewer accepted review: 2022-06-06 12:18

Reviewer performed review: 2022-06-06 13:17

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [ ] Anonymous [ ] Onymous</td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

All changes were made, may proceed for publication. thank you and good luck
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 74665

Title: Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03072151

Position: Editorial Board

Academic degree: MD, MSc

Professional title: Associate Professor, Attending Doctor, Surgeon

Reviewer’s Country/Territory: Taiwan

Author’s Country/Territory: China

Manuscript submission date: 2022-02-11

Reviewer chosen by: Li-Li Wang

Reviewer accepted review: 2022-06-07 13:55

Reviewer performed review: 2022-06-07 15:45

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
I am very sorry but you did not convince me with the revision. 1. There is no signature from patient/family in the signed consent! 2. Although this article is not a clinical trial or case-control study, the authors are encouraged to discuss alternative ways to treat the patient in discussion.